ASCO 2025: Opening a New Era of "Cancer Eradication"ASCODiscover the latest breakthroughs from ASCO 2025, including innovative cancer treatments, immunotherapy advances, bispecific antibodies, and promising breast cancer therapies shaping the future of oncology.
Bicara and Merus Compete in HNSCC Drug Development RaceASCOBicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
Proposed NIH Cancer Research Cuts Spark Industry ConcernASCOThe Trump administration’s proposed budget cuts to NIH and NCI risk hindering cancer research progress, prompting strong opposition from ASCO and ACS CAN over potential impacts on patient outcomes and innovation.
Kura and Kyowa's Ziftomenib Shows 23% Remission in AML TrialASCOKura Oncology and Kyowa Kirin announced a 23% remission rate in their phase 2 trial of oral leukemia drug ziftomenib for relapsed/refractory NPM1-mutant AML, with FDA approval under review and phase 3 trials planned.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
